Danaher (DHR) is a publicly traded Healthcare sector company. As of May 20, 2026, DHR trades at $170.58 with a market cap of $115.98B and a P/E ratio of 32.77. DHR moved +2.50% today. Year to date, DHR is -27.29%; over the trailing twelve months it is -13.48%. Its 52-week range spans $160.93 to $279.59. Analyst consensus is strong buy with an average price target of $230.40. Rallies surfaces DHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Danaher Raises 2026 EPS Guidance to $8.35–$8.55 and Plans Masimo Acquisition: Danaher reported Q1 2026 revenue of $6.0 billion, up 3.5% year-over-year, and non-GAAP EPS of $2.06, a 9.5% increase driven by Bioprocessing and Life Sciences strength. The company raised full-year adjusted EPS guidance to $8.35–$8.55 and announced plans to acquire Masimo to expand its patient monitoring portfolio.
| Metric | Value |
|---|---|
| Price | $170.58 |
| Market Cap | $115.98B |
| P/E Ratio | 32.77 |
| EPS | $5.19 |
| Dividend Yield | 0.40% |
| 52-Week High | $279.59 |
| 52-Week Low | $160.93 |
| Volume | 3.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $24.78B |
| Net Income | $3.69B |
| Gross Margin | 58.94% |
16 analysts cover DHR: 0 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $230.40.